Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 6
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Langer, Astrid Holle, Rolf and John, Jürgen 2012. Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening. BMC Health Services Research, Vol. 12, Issue. 1,


    Prosser, Lisa A. Grosse, Scott D. Kemper, Alex R. Tarini, Beth A. and Perrin, James M. 2012. Decision analysis, economic evaluation, and newborn screening: challenges and opportunities. Genetics in Medicine, Vol. 14, Issue. 8, p. 703.


    Bodamer, Olaf A. 2010. Dépistage de la phénylcétonurie. Annales Nestlé (Ed. française), Vol. 68, Issue. 2, p. 55.


    Langer, A. and John, J. 2009. Neugeborenenscreening im Spannungsfeld der Gesundheitsökonomie. Monatsschrift Kinderheilkunde, Vol. 157, Issue. 12, p. 1230.


    Norman, Richard Haas, Marion and Wilcken, Bridget 2009. International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions. Health Policy, Vol. 89, Issue. 3, p. 252.


    Haas, Marion Chaplin, Meredyth Joy, Pamela Wiley, Veronica Black, Carly and Wilcken, Bridget 2007. Healthcare Use and Costs of Medium-chain Acyl-Coa Dehydrogenase Deficiency in Australia: Screening Versus No Screening. The Journal of Pediatrics, Vol. 151, Issue. 2, p. 121.


    ×
  • International Journal of Technology Assessment in Health Care, Volume 22, Issue 3
  • July 2006, pp. 321-326

Economics of tandem mass spectrometry screening of neonatal inherited disorders

  • Abdullah Pandor (a1), Joe Eastham (a2), James Chilcott (a1), Suzy Paisley (a1) and Catherine Beverley (a1)
  • DOI: http://dx.doi.org/10.1017/S026646230605121X
  • Published online: 01 July 2006
Abstract

Objectives: The aim of this study was to evaluate the cost-effectiveness of neonatal screening for phenylketonuria (PKU) and medium-chain acyl-coA dehydrogenase (MCAD) deficiency using tandem mass spectrometry (tandem MS).

Methods: A systematic review of clinical efficacy evidence and cost-effectiveness modeling of screening in newborn infants within a UK National Health Service perspective was performed. Marginal costs, life-years gained, and cost-effectiveness acceptability curves are presented.

Results: Substituting the use of tandem MS for existing technologies for the screening of PKU increases costs with no increase in health outcomes. However, the addition of screening for MCAD deficiency as part of a neonatal screening program for PKU using tandem MS, with an operational range of 50,000 to 60,000 specimens per system per year, would result in a mean incremental cost of −£17,298 (−£129,174, £66,434) for each cohort of 100,000 neonates screened. This cost saving is associated with a mean incremental gain of 57.3 (28.0, 91.4) life-years.

Conclusions: Cost-effectiveness analysis using economic modeling indicates that substituting the use of tandem MS for existing technologies for the screening of PKU alone is not economically justified. However, the addition of screening for MCAD deficiency as part of a neonatal screening program for PKU using tandem MS would be economically attractive.

Copyright
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: